Metformin and B12 Depletion

Healthcare · §638

Take metformin long enough and your vitamin B12 quietly drains away. About 1 in 14 long-term users crosses into measurable deficiency over four to five years — and the early signs (foot tingling, brain fog, bone-deep tired) get written off as diabetes or as aging. One blood test catches it. A cheap pill fixes it. Nobody flags it because the damage takes a decade to surface.

Test · Yearly Evidence Moderate Chapter Healthcare

The whole thing is small: ask for a B₁₂ check at your next annual labs. If the number is low, take a pill. Catch it early and the tingling, the fatigue, the slow morning brain reverse in weeks — miss it for a decade and the nerve damage stops being reversible. Under $100 a year, two minutes of your time. Almost no one disputes it's worth doing; the only argument is whether everyone should be tested yearly or only the people who notice symptoms.

Metformin is a positively charged molecule that travels through your gut as you swallow it. It binds calcium at the surface of the cells in the last stretch of the small intestine — the same cells whose job is to grab vitamin B₁₂ from food and ferry it into the bloodstream. That pickup is calcium-dependent, and metformin sits in the way of it. The proof is direct: feed patients on metformin extra calcium, and B₁₂ absorption returns to normal Bauman 2000.

This is a slow-acting problem. Your liver stores 2 to 5 milligrams of B₁₂ and you only use about 2 micrograms a day, so the tank takes three to five years to run low even with the pipe partially shut. Which is why people on metformin for one or two years almost never have a B₁₂ problem — and people on it for six or eight years often do.

How sure are we, and how big

The cleanest data come from a Dutch placebo-controlled trial: 390 people with type 2 diabetes, half put on metformin and half on a sugar pill, followed for over four years with regular B₁₂ blood draws. Mean B₁₂ dropped about a fifth in the metformin group. Roughly 1 in 14 patients crossed into outright deficiency who wouldn't have on placebo de Jager 2010.

The longer-term picture comes from a 13-year follow-up of metformin users in the Diabetes Prevention Program. At year 13, around 7 in 100 metformin users had biochemical B₁₂ deficiency, against 5 in 100 on placebo. Borderline-low B₁₂ reached about 1 in 5 of the metformin group. Each gram-year of metformin pushed the odds of deficiency up by another 13% Aroda et al. 2016. A US population survey confirmed the same pattern in the real world: metformin users had roughly double the B₁₂ deficiency rate of similar non-users Reinstatler et al. 2012.

Risk climbs with both dose and time. Below 1 gram a day or three years of use, the signal is faint; above 2 grams a day past four years, it's loud. Each gram of daily dose roughly triples the odds of deficiency Ting et al. 2006.

What years of quiet deficiency look like

The deficiency takes years to surface, and that's why most people miss it. The first sign isn't anemia. It's a creeping kind of tired that sleep doesn't fix — the 7 am alarm gets harder, the morning coffee that used to lift you to a clean alertness now lifts you to mediocre. Your partner mentions you seem dimmer lately, more "somewhere else." Words you used to grab without thinking take an extra second; you laugh it off as getting older.

Then the feet. A faint pins-and-needles on the bottom of one foot, the kind you get from sitting wrong. It comes and it goes. A year later it's there most evenings, both feet. You mention it to your doctor and the answer is "that's the diabetes" — and gabapentin gets prescribed for what is actually a vitamin deficiency you've had for four years.

From here, the clock matters. Caught inside the first year of clinical deficiency, the tingling and the fatigue reverse with a pill. Left longer, the nerve damage drifts toward permanent — the dorsal columns of the spinal cord can lose myelin in a way that doesn't fully come back Wile and Toth 2010. The fatigue becomes baseline. The cognitive dulling gets logged as aging. The balance gets worse and a fall in your seventies turns into a hip fracture in a way that wasn't preordained. By the time anybody thinks to check B₁₂, the early window is closed.

What to actually do

Get a serum B₁₂ drawn with your annual diabetes labs. It rides along on the existing blood draw — no extra appointment, usually covered by insurance. If the number comes back at the low end of "normal" (between 200 and 300 picograms per millilitre), ask for methylmalonic acid as well. That's the marker that detects the cellular shortage when the standard B₁₂ number still looks fine Out et al. 2018.

The American Diabetes Association now recommends periodic B₁₂ monitoring in metformin-treated patients ADA 2024; NICE in the UK does the same NICE 2022. Fewer than a third of long-term metformin patients actually get the test in practice, which is why it usually falls to the patient to ask for it.

Who should push to test earlier

Anyone on metformin for more than two years should be in the testing routine. A handful of groups should start sooner and test more often:

Vegetarians and vegans — B₁₂ is an animal-source vitamin; you started with less in the tank, so the metformin drain bites earlier.
People on daily acid blockers (omeprazole, pantoprazole, esomeprazole, famotidine, ranitidine and the like) — stomach acid is needed to release B₁₂ from food, so chronic acid suppression piles onto the metformin problem. This is the highest-risk common combination.
Anyone over 65 — the stomach lining thins with age, which independently cuts B₁₂ absorption. Roughly 1 in 5 adults past 60 has the underlying gastritis whether they know it or not.
People who've had bariatric surgery or part of the stomach removed — the cells that make the carrier protein for B₁₂ are gone or reduced.
Anyone on 2 grams a day or more — depletion scales with dose, and the high-dose long-term group is where the deficiency curves bend sharply upward Ting et al. 2006.
Off-label users — people taking metformin for PCOS, weight, or longevity. You sit in the same dose-and-time window as the trial data, but you're rarely flagged for monitoring by a clinician focused on the off-label reason.

What "normal B12" misses

"My B₁₂ came back normal." Normal here is misleading. The reference range was set decades ago against blood findings; the lower end of it (200 to 300 pg/mL) is where many people already have functional deficiency at the cellular level — detectable on the methylmalonic acid test but invisible on the standard one Out et al. 2018. If your number sits in that range and you have tingling, fatigue, or foggy thinking, push for MMA before accepting the all-clear.

"B₁₂ deficiency makes you anemic — I'm not anemic, so I'm fine." The neurological version of B₁₂ deficiency can lead the blood version by years, especially in anyone eating a lot of fortified grain — which is most people on a Western diet. Folate from fortified flour masks the blood changes while doing nothing for the nerve damage. The blood is the last warning, not the first.

Where this goes wrong in practice

The classic miss: a long-term metformin patient develops foot tingling, the chart says "diabetic peripheral neuropathy," and a gabapentin or pregabalin prescription closes the case. The B₁₂ was never checked. Years later the patient has permanent loss of sensation and gait imbalance, and the deficiency they walked in with — fixable for the price of a generic supplement — is now baked into the picture Wile and Toth 2010.

The other miss is quieter. B₁₂ is tested once at year two ("looks fine"), recorded as the baseline, and never tested again. The deficiency arrives between year four and year seven and goes uncaught because nobody scheduled the follow-up. The fix on both is the same: an annual B₁₂ on the standing labs list, not a one-off check.

What changes when you catch it

If you test and you're fine, you've spent fifteen dollars and one extra blood draw. If you test and you're borderline, you take a pill that costs less than a coffee per month, and the number comes back into range over the next eight weeks. Hematologic markers normalise inside two months Mahajan and Gupta 2010. If you'd already been picking up early symptoms — the slow morning brain, the bottom-of-foot tingling, the harder-to-place tiredness — most of those reverse over weeks to a few months.

The bigger payoff is what doesn't happen. The next decade doesn't include the slow slide from "a little tired" to "I sleep but I don't recover." The neuropathy that does eventually arrive — most long-term diabetics do develop some — arrives later and lighter because you didn't stack a vitamin deficiency on top of the diabetes. The doctor visit five years from now where you'd have walked in with three new symptoms and walked out with two more prescriptions ends instead with "looks good, see you next year." Your seventies still include the morning walk you took for granted in your fifties — your feet still feel the ground, your balance still trusts itself, and the fall that would have ended that chapter doesn't happen.

Adjacent territory

Diabetic peripheral neuropathy — the broader nerve-damage picture that the B₁₂ piece often hides inside of.
Long-term acid blockers (PPIs) — same B₁₂ story by a different route; compounds with metformin when the two are stacked.
Methylmalonic acid testing — the cellular-level marker that catches deficiency before the standard B₁₂ number drops.
Metformin for longevity — the off-label use case, with the same B₁₂ consequences and none of the diabetes-care machinery that usually catches them.
Atrophic gastritis in older adults — the underlying absorption problem that compounds with both metformin and acid suppression past 65.

Related in the handbook

Worsens / aggravates

— This is the mechanism: metformin drains B12 over years, which is why diabetics on it need the level checked.

— The B12 metformin drains also feeds the inner ear; the depletion can show up as faster hearing loss.
— Metformin can push you into true cellular B12 shortage even when the basic number looks okay — worth the deeper tests.
— Anyone started on metformin for new diabetes should have B12 monitored; the depletion is slow and silent.
— B12 drained by metformin shows up as oversized red cells — a quiet clue on a routine blood count.
— Many people taking metformin long-term are doing so for PCOS or its insulin resistance, exactly the group that forgets to check B12.

Substance and claimed effects

Metformin (dimethylbiguanide) is the first-line oral therapy for type 2 diabetes and the most-prescribed antidiabetic agent worldwide, also used off-label for prediabetes, polycystic ovary syndrome, weight management, and gestational diabetes prevention. Chronic use (typically defined as >3–4 years, or cumulative dose >3 g-years) lowers serum vitamin B₁₂ in a dose- and duration-dependent fashion through interference with calcium-dependent ileal absorption of the intrinsic-factor–B₁₂ complex Bauman et al. 2000. The clinical consequences this entry covers: laboratory-defined B₁₂ deficiency, elevated methylmalonic acid (MMA) and homocysteine as functional markers, peripheral neuropathy that worsens or mimics diabetic neuropathy, megaloblastic anemia in a minority, and probable contribution to cognitive symptoms in the elderly. The intervention is monitoring (annual serum B₁₂, MMA when borderline) and supplementation when low — not discontinuation of metformin, whose cardiovascular and glycemic benefits dominate the trade-off.

Evidence by addressing question

mechanism

The textbook story is calcium displacement at the ileal terminus of B₁₂ absorption. Dietary B₁₂ binds intrinsic factor (IF) in the stomach; the IF-B₁₂ complex traverses the small intestine and is taken up by cubilin receptors on the apical surface of ileal enterocytes in a calcium-dependent process. Metformin, a positively charged biguanide, antagonises this step — postulated mechanisms include direct interference with the IF-cubilin interaction and disruption of the cation-dependent uptake by competing for calcium. Bauman et al. 2000 demonstrated the mechanism's calcium-dependence directly: oral calcium carbonate supplementation (1.2 g/day for one month) reversed metformin-induced B₁₂ malabsorption in 7 of 7 affected patients, restoring uptake on Schilling test. The implication: metformin does not destroy B₁₂ stores or alter hepatic recycling — it cuts off the input pipe, and stores deplete over years.

Additional mechanistic threads carry less weight but should be flagged. Metformin alters bile-acid kinetics and increases B₁₂ losses in bile; it shifts the small-intestinal microbiome (notably increasing Escherichia and decreasing Intestibacter), which may consume B₁₂; and it inhibits enterocyte cobalamin uptake by perturbing intracellular calcium signalling at concentrations achieved at standard dosing. None of these is dominant; the calcium-dependent IF-cubilin story is the consensus mechanism. The latency is consistent with the depletion-of-stores model — hepatic B₁₂ stores are 2–5 mg against a daily turnover near 2 µg, so a partial absorption block takes 3–5+ years to surface biochemically and longer to produce symptoms de Jager et al. 2010.

evidence

The keystone trial is the HOME study de Jager et al. 2010: 390 insulin-treated type 2 diabetics, randomised to metformin (titrated to 850 mg three times daily) or placebo, followed for a mean 4.3 years. Mean serum B₁₂ fell 19% in the metformin arm relative to placebo (95% CI -24% to -14%); B₁₂ deficiency (<150 pmol/L) occurred in 9.9% vs 2.7% of placebo (absolute risk increase 7.2%, NNH ~14). Homocysteine rose 5% over the same window. Critically, this was an RCT with biochemically verified endpoints — not a registry or pharmacovigilance signal.

The longest-duration human data comes from the Diabetes Prevention Program Outcomes Study Aroda et al. 2016: 13.3-year follow-up of the original DPP cohort (n=1,073 metformin-randomised at baseline). At year 5, low B₁₂ (≤203 pg/mL or ~150 pmol/L) was present in 4.3% of metformin-treated vs 2.3% of placebo (p=0.02); at year 13, 7.4% vs 5.4% (p=0.12, narrowing as background supplementation rose). Combined low or borderline-low B₁₂ reached 19% in the metformin arm at year 5. Risk rose with cumulative exposure: each gram-year of metformin associated with a 13% increase in odds of B₁₂ deficiency.

Cross-sectional NHANES analysis Reinstatler et al. 2012: 5.8% biochemical B₁₂ deficiency in metformin-treated US diabetics versus 2.4% in non-metformin-treated diabetics and 3.3% in non-diabetic adults. Concurrent multivitamin or B₁₂ supplementation attenuated but did not eliminate the deficit. Borderline-low B₁₂ (200–300 pg/mL) was nearly twice as common in metformin users.

Dose-response confirmed in case-control work: Ting et al. 2006 found an odds ratio of 2.88 per 1 g/day current metformin dose (95% CI 2.15–3.87) and 2.39 per 3 years of cumulative use. Risk is essentially absent below 1 g/day and below 3 years; it climbs steeply above 2 g/day past 4 years.

Functional markers: serum B₁₂ alone misclassifies. Methylmalonic acid (MMA), elevated when intracellular B₁₂ is insufficient for the methylmalonyl-CoA mutase reaction, rises before serum B₁₂ falls to overt-deficient range. The HOME-trial post hoc Out et al. 2018 showed mean MMA rose 5% per year of metformin treatment, and elevated MMA was already detectable at serum B₁₂ levels in the low-normal (200–300 pg/mL) zone in metformin-treated patients.

protocol

The American Diabetes Association's 2024 Standards of Care ADA 2024 recommends periodic measurement of vitamin B₁₂ in metformin-treated patients, "especially in those with anemia or peripheral neuropathy." Annual screening is the typical interpretation; some endocrinologists test biennially in lower-risk patients. NICE NG28 NICE 2022 recommends testing B₁₂ in metformin-treated patients with symptoms of deficiency.

Thresholds: a serum B₁₂ below 150 pmol/L (~200 pg/mL) is overt deficiency; 150–220 pmol/L (200–300 pg/mL) is the diagnostic grey zone where MMA and homocysteine should be checked. Elevated MMA (>0.40 µmol/L) with low or borderline B₁₂ confirms functional deficiency.

Supplementation: oral cobalamin 1,000 µg/day reliably corrects deficiency even in absorption-impaired states, because ~1% is absorbed by passive diffusion independent of IF — a 1000 µg dose delivers ~10 µg passively, far exceeding the 2 µg/day requirement. Intramuscular cyanocobalamin 1,000 µg weekly for 4–8 weeks then monthly is the legacy regimen, still preferred in symptomatic neurological cases for faster correction. Calcium supplementation (1.2 g/day) reverses absorption defect Bauman et al. 2000 but is no longer the standard intervention — oral B₁₂ is cheaper and more reliable.

Discontinuation of metformin is not indicated. The cardiovascular and glycemic benefits — and lower cancer risk in observational data — dominate the B₁₂ trade-off, which is fully managed by supplementation.

contraindications

The "contraindications" framing inverts here — there are no contraindications to monitoring or supplementing B₁₂. The question is which metformin users are at elevated baseline risk and warrant earlier or more frequent screening:

Vegetarians and vegans — already at risk from low dietary B₁₂ (animal-source-only nutrient).
Long-term proton pump inhibitor (PPI) or H₂ blocker users — reduced gastric acid impairs B₁₂ release from food.
Patients over 65 — atrophic gastritis affects ~20% of this group and independently impairs B₁₂ absorption.
Post-gastrectomy or post-bariatric patients — loss of intrinsic-factor-producing parietal cells.
Patients with diabetic peripheral neuropathy on metformin — even with normal serum B₁₂, MMA should be checked.
Patients on metformin doses ≥2 g/day for ≥4 years.

misconceptions

The most consequential misconception is treating "normal" serum B₁₂ (200–300 pg/mL) as adequate. The reference range was established before functional-marker data; up to a third of patients with B₁₂ in this range have elevated MMA and clinical or subclinical deficiency Out et al. 2018. The second misconception is attributing all peripheral neuropathy in a metformin-treated diabetic to diabetes itself: Wile and Toth 2010 documented worsened neuropathy scores in metformin-treated diabetics with elevated MMA versus matched controls, and improvement after B₁₂ repletion in a subset. The third is that B₁₂ deficiency requires anemia to manifest. Neurological symptoms — paresthesias, sensory ataxia, cognitive dulling — can precede hematologic changes by years, especially when folate intake is high (as it is for many diabetics on fortified-grain diets), because folate masks the megaloblastic morphology while doing nothing for the neurological pathway.

failure-modes

The dominant clinical failure mode is silent depletion mistaken for diabetic complications. A patient is on metformin for 6 years, develops tingling and numbness in the feet, and the symptoms are charted as diabetic peripheral neuropathy — meanwhile the underlying deficiency progresses to subacute combined degeneration of the spinal cord, which can become irreversible Wile and Toth 2010. The corollary failure: serum B₁₂ ordered, returns "low-normal," patient reassured. MMA was never checked. Other failure modes: a single normal B₁₂ at year 2 used as baseline reassurance with no follow-up; supplementation prescribed but adherence not verified (oral 1000 µg/day is effective only if actually taken); discontinuation of metformin attempted in lieu of supplementation, with predictable glycemic decompensation.

stakes

Untreated, the neurological pathway of B₁₂ deficiency is progressive and partially irreversible. Early features — paresthesias, reduced vibration sense, gait imbalance — usually resolve with repletion if caught within months. Subacute combined degeneration, the late myelin loss in dorsal and lateral columns, can leave permanent sensory and motor deficits if treatment is delayed beyond 6–12 months de Jager et al. 2010. Cognitive consequences are more contested: observational data link metformin use, low B₁₂, and impaired cognitive performance in older adults, but the effect size is modest and confounded by diabetes itself. The DPPOS data Aroda et al. 2016 suggest that with 10+ years of metformin exposure, roughly 1 in 13 patients will have biochemical deficiency at any given point — not a vanishing risk at population scale.

payoff

The intervention is one of the cheapest in clinical medicine and one of the highest-leverage when the diagnosis is right. A serum B₁₂ assay costs ~$25–50; MMA ~$50–100; cyanocobalamin tablets are pennies per day; the entire annual monitoring + supplementation cost falls under $100. Early neurological symptoms reverse over weeks-to-months with repletion. Hematologic abnormalities normalise in 4–8 weeks Mahajan and Gupta 2010. The harder-to-quantify payoff: avoidance of the labelling cascade ("diabetic neuropathy") that leads to gabapentin prescriptions, escalating dose, and resignation to permanence in a deficiency that was reversible.

The credibility range

Optimist case (this is real, this is meaningful, monitor everyone)

The mechanism is established and reproducible — calcium-dependent ileal interference with IF-B₁₂ uptake, demonstrated in vitro and reversed by calcium in vivo Bauman et al. 2000. The RCT data are unambiguous: ~7% absolute increase in biochemical deficiency over 4 years de Jager et al. 2010. Long-term data show the trajectory continues — ~1 in 13 deficient at 13 years on metformin Aroda et al. 2016. Functional markers (MMA, homocysteine) detect deficiency at serum B₁₂ levels still inside the "normal" range, so the population at clinical risk is larger than the population at lab-defined risk. Neurological consequences are partially irreversible if missed. The screening test is cheap, the supplementation is cheap, and the only harm of overdiagnosis is unnecessary B₁₂ intake — which has no toxicity ceiling. The case for universal annual screening in long-term metformin users is overwhelming. Several jurisdictions (NICE, ADA) now formally endorse this ADA 2024 NICE 2022.

Skeptic case (this is overhyped, most deficiency is biochemical not clinical, don't medicalise)

The HOME-trial absolute risk increase was 7% over 4.3 years for biochemical deficiency, not clinical syndrome de Jager et al. 2010. Symptomatic, hematologic, or neurologic deficiency attributable to metformin remains uncommon — most "metformin-induced B₁₂ deficiency" is a lab number, not a sick patient. The neurological signal in observational neuropathy studies Wile and Toth 2010 is confounded by diabetes duration, glycemic control, age, and alcohol — metformin-using diabetics are by definition the longer-disease-duration cohort. Cognitive claims are largely retrospective with small effect sizes. Population screening could detect deficiency in patients who would never have developed clinical disease, costing assays and supplements that buy little real benefit. And the conventional reference range was constructed against observed clinical outcomes — moving to MMA-based diagnosis lowers the bar to include people whose B₁₂ is functionally adequate.

Author's call

The mechanism, the dose-response, the RCT-grade evidence, and the irreversibility of late neurological consequences put this on the high-evidence side. The intervention is cheap and harmless. The cost-benefit asymmetry is strong enough that the skeptic case loses on stakes — even granting that only ~1 in 7 metformin-induced deficiencies will produce a clinical syndrome, the screening cost is trivial against the cost of a missed case progressing to subacute combined degeneration. Land squarely on the side of: annual serum B₁₂ in all long-term metformin users; MMA when borderline; oral 1,000 µg/day cobalamin when low or low-normal-with-elevated-MMA; do not discontinue metformin.

Stakeholder and incentive map

Endocrinology societies and guideline bodies (ADA, NICE, EASD) — moved over the 2010s from "consider" to "recommend periodic monitoring," driven by the HOME and DPPOS data. Incentive: defensible practice standards; some lag from updating cycles.
Primary care — where most metformin is prescribed and where most B₁₂ monitoring fails to happen. Incentive against: time, busy panels, no automatic reminders in many EHRs. Surveys consistently show <30% of long-term metformin users get annual B₁₂ testing.
Diabetes pharma — no incentive either way; metformin is generic, the depletion finding doesn't affect prescribing volume.
Supplement industry — modest commercial interest in B₁₂ formulations; methylcobalamin variants marketed at premium against simpler cyanocobalamin without strong differential-effectiveness data.
Patient communities (r/diabetes, diabetes.co.uk forums, T2D Facebook groups) — high awareness of the B₁₂ issue; community signal is loud and consistent; many patients report self-supplementing after reading the literature themselves.
Neurology — has long warned against missed B₁₂ in any peripheral neuropathy workup; sees the failure-mode cases when they arrive at neuropathy clinic.

Population variability

Risk is non-uniform across the metformin-treated population. Modifiers, in approximate order of magnitude:

Cumulative dose-time exposure dominates. Below 1 g/day or 3 years of use, the deficiency signal is weak; above 2 g/day past 4–5 years, prevalence climbs sharply Ting et al. 2006 Aroda et al. 2016.
Dietary intake. Vegans and strict vegetarians have low baseline stores; they cross the deficiency threshold years earlier than omnivores on the same metformin exposure.
Age. Atrophic gastritis affects 10–30% of adults over 60; combined with metformin, the absorption deficit compounds. Older patients are also where the cognitive and neuropathic stakes are highest.
Concurrent acid-suppression therapy. Long-term PPI use independently doubles B₁₂ deficiency risk; metformin-plus-PPI is the highest-risk common combination.
Bariatric surgery history. Loss of intrinsic-factor-producing parietal cells means metformin's effect compounds with an already-marginal absorption pathway.
Genetic variation. Polymorphisms in FUT2, TCN2, MTHFR, and CUBN affect baseline B₁₂ handling but are not yet clinically actionable for individual risk stratification.
Calcium intake. Low dietary calcium plausibly worsens the absorption defect, given the mechanism. Not yet a screening criterion.

The catalogue reader most affected is the long-term diabetic or PCOS patient on metformin for years; the prediabetic on metformin extension-of-life protocols; and the increasingly visible "metformin for longevity" off-label user. The last group is particularly relevant: long-duration low-dose metformin in non-diabetic adults is the exact profile the DPPOS data warn about, often without any monitoring.

Knowledge gaps

The MMA-defined population. The clinical significance of isolated MMA elevation at "normal" serum B₁₂ in metformin users is incompletely characterised. We don't know what fraction of that population, untreated, develops clinical syndromes over 10+ years.
Cognitive endpoints. Observational links between metformin-induced B₁₂ deficiency and cognitive decline exist but no RCT has tested whether supplementation in metformin users with low-normal B₁₂ protects cognition. The relevant trial would take a decade.
Off-label metformin populations. The DPPOS and HOME trials studied diabetic patients on full therapeutic doses. The growing population of non-diabetic adults using metformin for healthspan / longevity at lower doses has no equivalent long-term B₁₂ data.
Optimal supplementation dose for prevention vs treatment. 1,000 µg/day is the conservative treatment dose; whether 50–100 µg/day or sublingual variants would prevent deficiency in chronic metformin users without clinically meaningful undertreatment is not directly tested.
Functional ranges. The serum B₁₂ reference range remains based on hematologic outcomes; a functional-marker–based threshold appropriate for neurological prevention is not standardised.
Newer formulations. Extended-release metformin and the gut-restricted Metformin-DR investigational formulation may produce less B₁₂ depletion (since the absorption defect is in the ileum, gut-restricted formulations should preserve more ileal function), but head-to-head B₁₂ data are still sparse.

Scope. Topic brief named the mechanism (ileal absorption), monitoring cadence, supplementation thresholds, and effects on neuropathy and cognition. Article covers all four. Cognition is covered lightly — the observational literature linking metformin-associated low B₁₂ to cognitive decline is real but modest in effect size and confounded by diabetes itself, so the article surfaces it as "slow morning brain" and "cognitive dulling logged as aging" rather than as a standalone section. Reflected in the focus score (2, not 3) and discussed in the dossier's credibility range.

Action choice. Used action: test rather than do. The reader's primary action is annual screening; supplementation only fires conditional on the test result. Some readers will end up taking a pill daily, but framing the entry as "do — take B₁₂" would over-prescribe to the 90%+ of metformin users not yet deficient. test with a clear protocol for the supplement branch is the more honest call.

Rating difficulties. Most consequence dimensions (energy, focus, health-short-term) score 2 because the effect is real and meaningful for the deficient subset but modest at population level — only ~7–10% of long-term users are biochemically deficient, smaller fraction symptomatic. Scoring against the population-weighted effect rather than the per-deficient-patient effect. The longevity score of 1 reflects falls-prevention and slowed cognitive decline in the elderly tail, not a major mortality lever in its own right.

Excluded. Calcium co-supplementation as an alternative to oral B₁₂: mechanistically sound Bauman 2000 but no longer the standard intervention since oral cyanocobalamin is cheaper, simpler, and more reliable. Mentioned in the dossier, dropped from the article. Detailed differential-formulation discussion (methyl- versus cyano-cobalamin, sublingual versus tablet) — no clinical evidence of meaningful difference at supplementation doses; would clutter the protocol section.

Future links. When the following entries exist, this one should link to them: diabetic peripheral neuropathy; proton pump inhibitor long-term use; methylmalonic acid testing; metformin for longevity; atrophic gastritis. Currently surfaced as forward pointers in the closing section.

Separate-entry candidates. "Metformin for longevity" is a substantial entry on its own — different evidence base (TAME trial pending), different population (non-diabetic adults), different risk-benefit. Flagged for the backlog. "Methylmalonic acid as a B₁₂ marker" probably warrants its own entry too — applies beyond metformin users (elderly, vegans, PPI users, post-bariatric).

Audience scoping. Did not constrain by gender or age in meta. The substance applies to anyone on long-term metformin; risk modifiers (age over 65, dietary pattern, concurrent PPI) are surfaced inside the audience addressing section rather than as hard meta scoping, since they sharpen risk rather than defining the relevant population.

Contraindications. Left empty. The intervention is testing and oral B₁₂ — neither has a contraindication in the closed vocabulary. The metformin contraindications themselves (kidney disease, contrast imaging) are properties of metformin as a drug, not of this entry's action.